Header

UZH-Logo

Maintenance Infos

Synergistic Highly Potent Targeted Drug Combinations in different Pheochromocytoma Models including Human Tumor Cultures


Abstract

There are no officially approved therapies for metastatic pheochromocytomas apart from ultratrace 131I-MIBG therapy approved only in the United States. We have, therefore, investigated the anti-tumor potential of novel molecular-targeted approaches in murine pheochromocytoma cell lines (MPC/MTT), immortalized mouse chromaffin Sdhb-/- cells, 3D-pheochromocytoma tumor models (MPC/MTT spheroids) and human pheochromocytoma primary cultures. We identified the specific PI3Kα inhibitor BYL719 and the mTORC1 inhibitor everolimus as the most effective combination in all models. Single treatment with clinically relevant doses of BYL719 and everolimus significantly decreased MPC/MTT and Sdhb-/- cell viability. A targeted combination of both inhibitors synergistically reduced MPC and Sdhb-/- cell viability and showed an additive effect on MTT cells. In MPC/MTT spheroids, treatment with clinically relevant doses of BYL719 alone or in combination with everolimus was highly effective, leading to a significant shrinkage or even a complete collapse of the spheroids. We confirmed the synergism of clinically relevant doses of BYL719 plus everolimus in human pheochromocytoma primary cultures of individual patient tumors with BYL719 attenuating everolimus-induced AKT activation. We have thus established a method to assess molecular-targeted therapies in human pheochromocytoma cultures and identified a highly effective combination therapy. Our data pave the way to customized combination therapy to target individual patient tumors.

Abstract

There are no officially approved therapies for metastatic pheochromocytomas apart from ultratrace 131I-MIBG therapy approved only in the United States. We have, therefore, investigated the anti-tumor potential of novel molecular-targeted approaches in murine pheochromocytoma cell lines (MPC/MTT), immortalized mouse chromaffin Sdhb-/- cells, 3D-pheochromocytoma tumor models (MPC/MTT spheroids) and human pheochromocytoma primary cultures. We identified the specific PI3Kα inhibitor BYL719 and the mTORC1 inhibitor everolimus as the most effective combination in all models. Single treatment with clinically relevant doses of BYL719 and everolimus significantly decreased MPC/MTT and Sdhb-/- cell viability. A targeted combination of both inhibitors synergistically reduced MPC and Sdhb-/- cell viability and showed an additive effect on MTT cells. In MPC/MTT spheroids, treatment with clinically relevant doses of BYL719 alone or in combination with everolimus was highly effective, leading to a significant shrinkage or even a complete collapse of the spheroids. We confirmed the synergism of clinically relevant doses of BYL719 plus everolimus in human pheochromocytoma primary cultures of individual patient tumors with BYL719 attenuating everolimus-induced AKT activation. We have thus established a method to assess molecular-targeted therapies in human pheochromocytoma cultures and identified a highly effective combination therapy. Our data pave the way to customized combination therapy to target individual patient tumors.

Statistics

Citations

Dimensions.ai Metrics
9 citations in Web of Science®
7 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

46 downloads since deposited on 05 Sep 2019
18 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Endocrinology and Diabetology
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Endocrinology
Language:English
Date:1 November 2019
Deposited On:05 Sep 2019 11:40
Last Modified:29 Jul 2020 11:14
Publisher:Oxford University Press
ISSN:0013-7227
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1210/en.2019-00410
PubMed ID:31322702

Download

Green Open Access

Download PDF  'Synergistic Highly Potent Targeted Drug Combinations in different Pheochromocytoma Models including Human Tumor Cultures'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 5MB
View at publisher